Stephen Bardin resigned as CalciMedica's chief financial officer and principal accounting officer, effective immediately following the filing of the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. The departure is not due to any disagreement with management but rather to pursue another professional opportunity. CalciMedica develops therapies targeting calcium signaling pathways in inflammatory and fibrotic diseases.
